Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002 • 6,505 citations

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

2001 • 6,133 citations

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

1998 • 3,550 citations

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

2009 • 3,503 citations

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

2004 • 2,888 citations

Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line

1999 • 2,796 citations

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

2005 • 2,741 citations

Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus

2005 • 2,312 citations

Complete Replication of Hepatitis C Virus in Cell Culture

2005 • 2,239 citations

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

2009 • 2,114 citations

Binding of Hepatitis C Virus to CD81

1998 • 2,042 citations

Replication of hepatitis C virus

2007 • 1,308 citations

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

2010 • 1,137 citations

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 • 1,095 citations

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 • 1,025 citations

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

2003 • 907 citations

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site.

1999 • 730 citations

Telaprevir for Previously Treated Chronic HCV Infection

2010 • 711 citations

Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide

1996 • 707 citations

Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

2007 • 620 citations

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

1998 • 613 citations

Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor

2003 • 607 citations

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

2009 • 516 citations

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

2005 • 481 citations

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2

2004 • 441 citations

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

2006 • 401 citations

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

2007 • 383 citations

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

2008 • 348 citations

Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious Virions

2007 • 347 citations

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients

2004 • 338 citations

SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders

2007 • 317 citations

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

2009 • 316 citations

SCH 503034, a Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease, Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Alpha Interferon in Replicon Cells

2006 • 314 citations

Novel Insights into Hepatitis C Virus Replication and Persistence

2004 • 304 citations

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

2007 • 258 citations

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034

2006 • 237 citations

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis

2008 • 230 citations

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

2008 • 219 citations

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

2005 • 217 citations

The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture

2005 • 212 citations

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

2006 • 202 citations

Structure of the catalytic domain of the hepatitis C virus NS2-3 protease

2006 • 195 citations

C-type Lectins L-SIGN and DC-SIGN Capture and Transmit Infectious Hepatitis C Virus Pseudotype Particles

2004 • 194 citations

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C

2005 • 179 citations

Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

2004 • 164 citations

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

2009 • 156 citations

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy

2008 • 142 citations

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

2008 • 137 citations

Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus

2007 • 136 citations

Evidence for the Formation of a Heptameric Ion Channel Complex by the Hepatitis C Virus P7 Protein in Vitro

2006 • 132 citations

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

2008 • 131 citations

Hepatitis C virus entry: Molecular biology and clinical implications

2006 • 129 citations

In vitro selected Con1 subgenomic replicons resistant to 2′-C-Methyl-Cytidine or to R1479 show lack of cross resistance

2006 • 128 citations

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

2009 • 122 citations

Recent Progress in the Development of Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase

2007 • 111 citations

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

2008 • 110 citations

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

2008 • 108 citations

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

2008 • 102 citations

4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C

2009 • 87 citations

Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells

2004 • 80 citations

Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections.

2007 • 79 citations

66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS

2008 • 77 citations

Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

2009 • 76 citations

Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment

2009 • 72 citations

Evaluation of VCH-759 monotherapy in hepatitis C infection

2009 • 70 citations

HCV drug discovery aimed at viral eradication

2009 • 70 citations

NM 283, AN EFFICIENT PRODRUG OF THE POTENT ANTI-HCV AGENT 2′-C-METHYLCYTIDINE

2005 • 67 citations

1046 FIRST-IN-MAN DEMONSTRATION OF POTENT ANTIVIRAL ACTIVITY WITH A NUCLEOSIDE POLYMERASE (R7128) AND PROTEASE (R7227/ITMN-191) INHIBITOR COMBINATION IN HCV: SAFETY, PHARMACOKINETICS, AND VIROLOGIC RESULTS FROM INFORM-1

2009 • 63 citations

Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: A phase 1b multiple ascending dose study

2010 • 63 citations

10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS

2009 • 59 citations

50 ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209

2009 • 54 citations

Targeting host factors: A novel rationale for the management of hepatitis C virus

2009 • 52 citations

Allosteric Inhibition of the Hepatitis C Virus NS5B RNA Dependent RNA Polymerase

2006 • 52 citations

[50] ANTIVIRAL ACTIVITY OF THE NON-NUCLEOSIDE POLYMERASE INHIBITOR, HCV-796, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2b IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV

2007 • 52 citations

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

2008 • 50 citations

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

2008 • 45 citations

Rapid decrease of wild-type hepatitis C virus on telaprevir treatment

2008 • 38 citations

Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors

2008 • 37 citations

[14] CLEARANCE OF HCVRNA WITH VALOPICITABINE (NM) PLUS PEG-INTERFERON IN TREATMENT-NAIVE PATIENTS WITH HCV-1 INFECTION: RESULTS AT 24 AND 48 WEEKS

2007 • 34 citations

Reply

2004 • 32 citations

993 HIGH END-OF-TREATMENT RESPONSE (84%) AFTER 4 WEEKS OF R1626, PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOLLOWED BY A FURTHER 44 WEEKS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN

2008 • 29 citations

[783] SHORT-TERM ANTIVIRAL ACTIVITY AND SAFETY OF ACH-806 (GS-9132), AN NS4A ANTAGONIST, IN HCV GENOTYPE 1 INFECTED INDIVIDUALS

2007 • 25 citations

Virological analysis of patients receiving Telaprevir administered Q8H or Q12H with Peginterferon-Alfa-2A or -Alfa-2B and Ribavirin in treatment-naive patients with Genotype I hepatitis C: study C208

2009 • 23 citations

68 RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4

2008 • 22 citations

12 DETECTION OF RESISTANT VARIANTS IN THE HEPATITIS C VIRUS NS3 PROTEASE GENE BY CLONAL SEQUENCING AT LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH BOCEPREVIR

2009 • 19 citations

21 LOW LEVEL OF RESISTANCE, LOW VIRAL FITNESS AND ABSENCE OF RESISTANCE MUTATIONS IN BASELINE QUASISPECIES MAY CONTRIBUTE TO HIGH BARRIER TO R1626 RESISTANCE IN VIVO

2008 • 14 citations

In the new area of noninvasive markers of hepatocellular carcinoma

2006 • 13 citations

832 EVALUATION OF A 4 WEEK LEAD-IN PHASE WITH NITAZOXANIDE PRIOR TO NITAZOXANIDE+PEGINTERFERON IN TREATING CHRONIC HEPATITIS C

2008 • 7 citations

831 RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL OF NITAZOXANIDE IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4

2008 • 5 citations